drugset / Trial / NCT00514007

Study of Continuous OSI-906 Dosing

NCT00514007

Phase 1 Completed 95 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.

Timeline

Start
2007-06-18
Primary completion
2012-03-19
Completion
2012-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject linsitinib Small molecule Oral

Indications